Related by context. All words. (Click for frequent words.) 69 pharmacokinetic equivalence 67 maximal tolerated 65 comparator arm 65 CIMZIA TM certolizumab pegol 65 ACTEMRA TM 65 EDEMA3 trial 64 Ophena TM 64 active comparator 64 Proellex TM 64 analgesic efficacy 64 plus prednisone prednisolone 64 pegylated interferon peg IFN 64 Zemplar Capsules 63 riociguat 63 maximally tolerated dose 63 headache nasopharyngitis 63 mitoxantrone plus 63 evaluating tivozanib 63 achieved statistical significance 63 morphometric vertebral fractures 63 somatostatin analog 63 mg RDEA# 63 oral ridaforolimus 62 CIMZIA TM 62 #mg BID [001] 62 oxycodone CR 62 plus prednisone 62 desvenlafaxine succinate 62 sorafenib tablets 62 interferon gamma 1b 62 MAGE A3 ASCI 61 oral deforolimus 61 diabetic neuropathic pain 61 oxymorphone ER 61 phase Ib 61 zonisamide SR 61 mapatumumab 61 Pharmacokinetic parameters 61 CINQUIL 61 cannabinor 61 ARCALYST ® 61 Triapine R 61 DASISION 61 ATACAND 61 MoxDuo TM IR 61 alfa 2a 61 RoACTEMRA 61 INSPIRE Trial Phase III 61 teriflunomide 61 Zenvia ™ 61 successfully commercialize Iluvien 61 viral kinetics 61 Ereska 61 FOLFOX6 chemotherapy regimen 61 incyclinide 61 phase IIb study 61 salmeterol fluticasone 60 abacavir lamivudine 60 bicifadine 60 elagolix 60 Aptivus ® 60 forodesine 60 efficacy tolerability 60 estramustine 60 FUSILEV enhances 60 cisplatin gemcitabine 60 prednisone prednisolone plus 60 KRN# 60 GSK# [001] 60 sorafenib Nexavar 60 omega interferon 60 HGS ETR1 mapatumumab 60 budesonide pMDI 60 opioid naïve 60 pharmacodynamic PD 60 #mg BID [003] 60 GOUT 60 pharmacokinetic PK study 60 DAVANAT 60 statin monotherapy 60 solid tumors ZYBRESTAT 60 bovine thrombin 60 torsemide ER 60 trastuzumab Herceptin R 60 VELCADE melphalan 60 pain palliation 60 HGS ETR2 60 FOLPI 60 opioid induced bowel dysfunction 60 antipsychotic efficacy 60 velafermin 59 pharmacodynamic effects 59 ritonavir boosted 59 adjuvant colon cancer 59 CIMZIA ™ 59 ® lenalidomide 59 statistically significant efficacy 59 receiving XGEVA 59 gemcitabine carboplatin 59 SILENOR 59 AzaSite Plus 59 mg TID 59 ADCS CGIC 59 doxorubicin cyclophosphamide 59 darunavir r 59 baminercept 59 im peramivir 59 adenosine injection 59 relapsed MM 59 neratinib 59 pharmacodynamic properties 59 reactogenicity 59 CTAP# Capsules 59 steroid dexamethasone 59 nalbuphine ER 59 intravenous cyclophosphamide 59 carboplatin paclitaxel 59 DepoDur TM 59 peg IFN 59 gemifloxacin 59 #mg/day [001] 59 paliperidone ER 59 BRIM2 59 oral prodrug 59 TELINTRA 59 PEGINTRON TM 59 Imprime PGG 59 DexaSite 59 colesevelam HCl 59 mcg QD 59 oral rivaroxaban 59 BRIM3 59 diarrhea dyspepsia 59 O PPDS 59 Budesonide foam crofelemer 59 Phase III ADT 59 sumatriptan naproxen sodium 59 doxorubicin docetaxel 59 antiresorptive 59 apremilast 59 avosentan 59 zolmitriptan 59 Solorel TM 59 R# #mg BID 59 plus MTX 59 mTOR kinase 59 saline placebo 59 bronchodilatory 59 achieved ACR# 59 viral kinetic 59 PREZISTA r 59 alvimopan 58 LEP ETU 58 RSD# oral 58 sitaxsentan 58 CTA# Injection 58 urinary N telopeptide 58 neurologic progression 58 amrubicin 58 #mg doses [002] 58 oral diclofenac 58 Primary endpoints 58 zoledronate 58 infliximab monotherapy 58 Meets Primary Endpoint 58 Dual Opioid 58 lenalidomide dexamethasone 58 Zoraxel 58 unresectable HCC 58 cariprazine 58 mycophenolic acid 58 pregabalin Lyrica 58 vaginal progesterone gel 58 demonstrated antitumor activity 58 plus methotrexate 58 Androxal TM 58 Cimzia TM 58 mg kg BID 58 iniparib 58 ZOLINZA 58 AAG geldanamycin analog 58 tolterodine ER 58 alvespimycin 58 galiximab 58 Pharmacokinetic studies 58 Tarceva TM 58 TNF alpha selectively neutralizing 58 #I TM# 58 Panzem R NCD 58 BEMA TM LA 58 phase IIIb 58 tolerability pharmacokinetics 58 interferon ribavirin 58 induced tumor regression 58 oral methylnaltrexone 58 Pemetrexed 58 icatibant 58 ruxolitinib 58 HMG CoA reductase inhibitors 58 antiandrogen 58 ELACYT 58 candesartan cilexetil 58 plasma kallikrein inhibitor 58 glycoprotein IIb IIIa inhibitor 58 HGS# 58 PEGylated anti 58 budesonide foam 58 demonstrated clinically meaningful 58 pegylated liposomal doxorubicin 58 Femara letrozole 58 fosbretabulin 58 plus dexamethasone 58 Mg Uk 58 motesanib 58 lexidronam injection 58 pharmacokinetic parameters 58 NP2 Enkephalin 58 CRESTOR #mg 58 parecoxib 58 TTF Therapy 58 neutropenia thrombocytopenia 58 placebo controlled clinical 58 azilsartan medoxomil 58 nab paclitaxel 58 1mg 2mg 58 mcg BID 58 antiviral efficacy 58 #mg QD [001] 58 clevidipine 58 limiting toxicity DLT 58 tamoxifen Nolvadex ® 58 gp# vaccine 58 venlafaxine XR 58 docetaxel Taxotere ® 58 Q#IR 58 orally inhaled migraine 58 ZP PTH 58 spontaneous bowel movements 58 tapentadol ER 58 intravenous RSD# 58 pharmacodynamic parameters 58 tipranavir 58 phase IIa clinical 58 Capesaris 58 subcutaneous enoxaparin 58 YONDELIS 58 MGd 58 RLAI 58 midstage clinical 58 pertuzumab 58 antitumor effect 58 #mg QD [002] 58 FOLFOX6 58 TLK# 58 VaD 58 elotuzumab 58 locoregional recurrence 58 palifermin 58 CANCIDAS 58 OvaRex ® MAb 58 davunetide intranasal AL 58 NSABP C 57 APTIVUS 57 pharmacokinetics PK 57 paclitaxel carboplatin 57 lopinavir r 57 Forodesine HCl 57 placebo controlled studies 57 FROVA 57 NATRECOR ® 57 BNC# 57 overlapping toxicities 57 AZILECT 57 NOXAFIL Oral Suspension 57 IFN alfa 57 preclinical efficacy 57 tecarfarin 57 RAPAFLO TM 57 asthma immunotherapeutic 57 clinically meaningful improvements 57 Dyloject TM 57 Golimumab 57 rosuvastatin #mg 57 RECORD1 57 tenofovir emtricitabine 57 systemic immunosuppressive drugs 57 lanthanum carbonate 57 aplindore 57 RAPAFLO R 57 rEV# 57 visilizumab 57 Pivotal Phase III 57 serum phosphorous 57 #.#/#.# mmHg [001] 57 systemically administered 57 #:# randomization 57 #mg dose [003] 57 Carvedilol 57 paclitaxel cisplatin 57 AZX# 57 hemostatic efficacy 57 SNT MC# 57 mometasone 57 nicardipine 57 opioid naive 57 sulfonylurea glimepiride 57 pharmacokinetic characteristics 57 multicenter Phase II 57 Teriflunomide 57 maximal doses 57 levosimendan 57 antidepressant efficacy 57 Ophena 57 Crestor rosuvastatin 57 #mg/day [002] 57 Phase 1b clinical 57 thalidomide Thalomid 57 regorafenib 57 STRIDE PD 57 DDP# 57 FOSRENOL ® 57 LEXIVA r 57 catheter occlusion 57 NGX# 57 ANAVEX #-# [001] 57 ocular formulation 57 mg BID 57 phase IIb III 57 interferon alfa 2b 57 LymphoStat B TM 57 Peg IFN 57 antitumor effects 57 tocilizumab 57 AIR CF1 57 EOquin TM 57 peginterferon alpha 2a 57 ADVANCE PD 57 dalteparin 57 prulifloxacin 57 certolizumab 57 melphalan prednisone 57 NEVO ™ 57 tipranavir r 57 rimonabant #mg/day 57 MVA MUC1 IL2 57 lumbar spine BMD 57 pharmacodynamic profiles 57 ARB telmisartan 57 rabeprazole 57 SILENOR ™ 57 tiotropium bromide 57 balsalazide 57 brivaracetam 57 HCV RESPOND 2 57 q8h 57 ACUROX ® 57 proprietary intravenous formulation 57 recurrent malignant glioma 57 betamethasone dipropionate 57 limiting toxicity 57 Phase #b/#a 57 acyclovir Lauriad R 57 Platinol ® cisplatin 57 Temsirolimus 57 null responder HCV 57 mg QD 57 trospium 57 paclitaxel eluting stents 57 Randomized Double blind 57 thorough QT 57 DEB# 57 Archexin 57 Combination REOLYSIN R 57 APTIVUS r 57 mGluR5 NAM 57 thiazolidinedione TZD 57 adjuvant cisplatin 57 multicenter Phase III 57 norethindrone acetate 57 ExTRACT TIMI 57 Octreolin 57 BoNTA 57 erlotinib Tarceva ® 57 BZA CE 57 tibolone 57 Phase #b/#a trial 57 relapsed ovarian cancer 57 Aflibercept 57 pyridostigmine 57 NLX P# 57 cystinosis patients 57 efficacy 57 taxane resistant 57 PEG IFN 57 relapsed MCL 57 Phase Ib clinical 57 4mg/kg 57 ULTRAM ER 57 Dacogen injection 57 Vidaza ® 57 Spiegelmer ® 57 Soliris TM eculizumab 57 paroxetine sertraline 57 thetreatment 57 BRAF inhibitor 57 Phase 1a clinical 57 Dabigatran etexilate 57 ZACTIMA 57 canakinumab 57 pharmacologically active isomer 57 cromolyn sodium 57 Vildagliptin 57 ketoprofen patch 57 GAMMAGARD 56 IIIa inhibitor 56 phase IIa 56 EDEMA3 56 Contrave# 56 TRANSFORMS 56 CA4P 56 safinamide 56 clinically meaningful improvement 56 docetaxel chemotherapy 56 Multiple Ascending Dose 56 retinal vein occlusion induced 56 IOP lowering 56 GRN# 56 Thal Dex 56 oral FTY# 56 8mg/kg 56 CYP#D# inhibitor 56 equi analgesic doses 56 #mg ATC 56 Tolvaptan 56 Raptiva r 56 bortezomib Velcade 56 efficacy endpoint 56 weekly subcutaneous injections 56 GSK# [002] 56 Toremifene 56 1mg dose 56 oral chemotherapeutic agent 56 Afatinib 56 ACTEMRA 56 Xelox 56 remission CR 56 MERLIN TIMI 56 Targretin capsules 56 epirubicin cyclophosphamide 56 Ketotransdel 56 erythropoietic 56 recurrent metastatic 56 administered intranasally 56 Vidaza azacitidine 56 APTIVUS R 56 HGS ETR1 56 plus gemcitabine 56 goserelin 56 zafirlukast 56 aflibercept VEGF Trap 56 CR nPR 56 Viread Emtriva 56 complete cytogenetic response 56 cediranib 56 peginterferon alfa 2b 56 cardiac repolarization 56 compound INCB# 56 headache abdominal pain 56 EFAPROXYN 56 carbidopa levodopa 56 SPRYCEL ® 56 GW# [003] 56 plus COPEGUS 56 oxcarbazepine 56 omacetaxine mepesuccinate 56 bupropion SR 56 standard chemotherapy regimen 56 PD LID 56 LibiGel ® 56 Amrubicin 56 everolimus eluting stents 56 EVIZON 56 ribavirin RBV 56 recurrent glioblastoma multiforme 56 urocortin 2 56 R adefovir dipivoxil 56 tapentadol IR 56 pegaptanib 56 Pegasys plus Copegus 56 pegylated interferon alfa 2b 56 Oral NKTR 56 Bicalutamide 56 oxycodone IR 56 non selective NSAIDs 56 PSMA ADC 56 AEGR 56 serotonin norepinephrine reuptake inhibitor 56 Arikace 56 mg hydrochlorothiazide 56 REMINYL ® 56 somnolence dizziness 56 phase IIb trial 56 Vicinium TM 56 OMNARIS HFA 56 torezolid phosphate 56 Dextofisopam 56 relapsed myeloma 56 6R BH4 56 confirmatory clinical 56 Exelixis compounds 56 peak plasma concentrations 56 SILENOR TM 56 COMBIVIR 56 hyaluronidase enzyme 56 FASLODEX 56 valopicitabine 56 #mg BID [002] 56 pharmacokinetic profiles 56 neutropenic sepsis 56 undergoing elective percutaneous 56 MYDICAR ® 56 Navelbine 56 briakinumab 56 peg interferon 56 anti EGFR antibody 56 piperacillin tazobactam 56 MoxDuo 56 mg/m2 dose 56 RhuDex TM 56 class mGluR5 inhibitor 56 antiandrogens 56 nasopharyngitis headache 56 epoetin alpha 56 Neurodex 56 Phase IIIb clinical 56 humanised monoclonal antibody 56 dexanabinol 56 amifostine 56 systemic hypotension 56 Myocet 56 INVEGA ® 56 Bezielle 56 Prosaptide 56 selegiline 56 LT NS# 56 alicaforsen enema 56 ALGRX 56 DOXIL 56 urate lowering 56 MiStent DES 56 angiographic outcomes 56 Subgroup analyzes 56 Phase IIA 56 pamidronate 56 Zometa hazard 56 SYMBICORT pMDI 56 hoFH 56 ritonavir boosted atazanavir 56 analgesic medications 56 dexamethasone Decadron 56 phase IIb 56 blinded randomized placebo controlled 56 OncoVEX GM CSF 56 pioglitazone HCl 56 KAPIDEX 56 COPEGUS 56 PROCHYMAL 56 steroid refractory 56 CaPre TM 56 Known hypersensitivity 56 indiplon capsules 56 Cloretazine R VNP#M 56 ZOMIG 56 Phase IIb III 56 genotypic resistance 56 LYSTEDA 56 FOLFOX4 56 INTEGRILIN R eptifibatide Injection 56 tenofovir FTC 56 Long Term Efficacy 56 varespladib 56 dose limiting toxicities 56 Engerix B 56 pharmacokinetic studies 56 chemotherapy cisplatin 56 arzoxifene 56 Glycopyrrolate 56 paricalcitol 56 nonrandomized 56 FOLFIRI 56 relapsing multiple sclerosis 56 TORISEL 56 ACR# ACR# 56 adriamycin 56 mycophenolate mofetil MMF 56 ADAGIO study 56 TAXOTERE ® 56 MoxDuo IR 56 HuMax EGFr 56 Entereg R 56 Randomized clinical trials 56 endometrial hyperplasia 56 primary hypercholesterolemia 56 phase III isavuconazole 56 Intravitreal 56 bezafibrate 56 Diovan HCT 56 mg Pycnogenol 56 renal toxicity 56 bosutinib 56 breast tenderness bloating 56 pomalidomide 56 double blinded placebo 56 QTc prolongation 56 INVEGA ™ 56 radezolid 56 Tasigna prolongs 56 clomipramine 56 pharmacodynamic profile 56 evaluating Actimmune 56 inecalcitol 55 bone marrow reticulin deposition 55 Secondary endpoints include 55 nebulized formoterol fumarate 55 Matrix Phase 2b 55 myopathy rhabdomyolysis 55 Oral corticosteroids 55 dizziness nausea diarrhea 55 cyclophosphamide doxorubicin vincristine 55 aspirin clopidogrel 55 ularitide 55 AIR CF2 55 novel histone deacetylase 55 CCR9 antagonist 55 administered subcutaneously 55 Fulvestrant 55 ARIKACE ™ 55 GLYX 55 Xcytrin R 55 trastuzumab DM1 55 Betaferon ® 55 titrated glipizide 55 pharmacodynamic markers 55 antiarrhythmic 55 symptomatic VTE 55 Non inferiority 55 LEVAQUIN ® 55 registrational Phase 55 MAP# 55 tolerability profiles 55 Elocalcitol 55 clinically meaningful reductions 55 GLP toxicology studies 55 ORENCIA ® 55 Cloretazine 55 GLPG# 55 gadobutrol 55 orally inhaled 55 neutropenia dehydration dyspnea 55 #mg dosing 55 multicenter placebo controlled 55 dose proportionality 55 CorVue ™ 55 placebo controlled trials 55 rilpivirine 55 Ceplene/IL-2 55 TNF alpha inhibitor 55 Prestara 55 CONBRIZA 55 telaprevir dosed 55 plus medroxyprogesterone acetate 55 urate lowering therapy 55 subcutaneous methylnaltrexone 55 visceral metastases 55 radiographic outcomes 55 Pharmacokinetics PK 55 Mycophenolate Mofetil 55 Lipitor #mg 55 ACE inhibitor ramipril 55 Ambrisentan 55 ICA # 55 anti arrhythmic 55 noninferiority 55 LAB CGRP 55 AVOREN 55 lasofoxifene 55 PASI scores 55 intermittent dosing 55 Trandolapril 55 clodronate 55 irbesartan 55 miconazole 55 pramlintide metreleptin combination 55 de novo kidney transplant 55 adjunctive placebo 55 Anturol TM 55 Folfox 55 immunomodulatory agents 55 phase IIb clinical 55 Itopride 55 TOCOSOL Camptothecin 55 LHRH receptor positive 55 omeprazole widely 55 antiangiogenic agents 55 CIPN 55 SYMMETRY trial 55 CLARITY study 55 EXPAREL ™ 55 Alocrest 55 NB S# strontium malonate 55 HyQ 55 extrapyramidal symptoms 55 Initiated Phase 55 dizziness somnolence 55 5 fluorouracil leucovorin 55 rHuPH# 55 mertansine 55 stage IIIb IV 55 FFNS 55 aflibercept 55 Doxil ® 55 rhITF 55 pharmacodynamics PD 55 antiangiogenic activity 55 custirsen 55 selective modulator 55 posaconazole 55 clinical endpoints 55 SinuNase TM 55 incidence ≥ 55 receptor tyrosine kinase inhibitor 55 octreotide LAR 55 Aggrastat ® tirofiban hydrochloride 55 beta carotene supplementation 55 Taxotere ® 55 Pennsaid R 55 febuxostat 55 confirmatory Phase III 55 Fast Track designations 55 EmbraceAC 55 sustained virological response 55 VIR# 55 octreotide acetate 55 docetaxel emulsion 55 atorvastatin #mg 55 Gemzar gemcitabine 55 Amplimexon 55 prucalopride 55 achieve statistical significance 55 pegylated interferon alfa 2a 55 Initiates Enrollment 55 platelet inhibitor 55 AERx ® 55 pCR 55 PEGylated interferon beta 1a 55 iloprost 55 5mg/kg 55 REOLYSIN ® 55 statistically significant p = 55 Fludara 55 favorable pharmacokinetic profile 55 refractory metastatic colorectal cancer 55 ALIMTA cisplatin 55 chronic angina 55 systemic corticosteroid 55 adjuvant GIST 55 treatment naive genotype 55 moderate hepatic impairment 55 Ovidrel 55 orBec 55 tezampanel 55 DCCR 55 assessing T DM1 55 hormone refractory metastatic prostate 55 AGILECT R 55 Ostarine 55 paclitaxel poliglumex 55 pegylated liposomal doxorubicin PLD 55 ostarine 55 ropinirole Requip 55 BrachySil 55 rufinamide 55 huC# DM4 55 SSRI SNRI 55 Cardiorespiratory fitness 55 cangrelor 55 placebo dexamethasone 55 signal detection CTSD 55 mg tid 55 insomnia somnolence 55 Val HeFT 55 ancrod 55 rimonabant #mg 55 ENMD # 55 Cleviprex TM clevidipine 55 dosage regimens 55 vidofludimus 55 Effexor venlafaxine 55 Perforomist Inhalation Solution 55 trastuzumab Herceptin ® 55 Rebif ® 55 Novolimus 55 inhibit platelet function 55 echinacea tablets 55 vasomotor symptoms 55 Elitek 55 plasma pharmacokinetics 55 hematological parameters 55 NasalFent 55 GetGoal Phase III 55 tolerability 55 enoximone 55 QT QTc 55 plus OBT 55 REVIVE Diabetes 55 medroxyprogesterone acetate 55 HORIZONS AMI 55 nonsteroidal 55 CA9 SCAN 55 Completes Patient Enrollment 55 ralfinamide 55 #mg dose [001] 55 secondary efficacy endpoints 55 evaluating Prochymal 55 PEGPH# 55 Pirfenidone 55 TASKi3 55 locoregional disease 55 Phase 1b trial 55 liposomal formulation 55 known sulfonamide allergy 55 5-FU/LV 55 oral picoplatin 55 oxypurinol 55 Subgroup analysis 55 Ocrelizumab 55 paclitaxel Taxol R 55 linaclotide treated 55 mycophenolate mofetil 55 albiglutide 55 3mg/kg 55 constipation nausea 55 prospectively defined 55 HCl capsules 55 NV1FGF 55 weekly CSBMs 55 mg dose 55 SVR# 55 ONCONASE R 55 prospective multicenter 55 Apidra ® 55 Maximum Tolerated Dose MTD 55 sulfonylurea metformin 55 venlafaxine ER 55 fluticasone salmeterol 55 immune modulating 55 dose escalation clinical 55 idarubicin 55 prospectively stratified 55 trials RCTs 55 Tarvacin Anti Cancer 55 topical diclofenac 55 preclinical pharmacokinetic 55 Combo Stent 55 ANAVEX #-# [002] 55 Darinaparsin 55 FM VP4 55 Zalypsis 55 VIRAMUNE 55 subcutaneous insulin 55 JAK inhibitor 55 tramiprosate Alzhemed TM 55 gemcitabine Gemzar 55 alpha 2a 55 Darusentan 55 Fondaparinux 55 Secondary efficacy endpoints 54 CINTREDEKIN BESUDOTOX 54 pharmacokinetic PK 54 recurrent herpes labialis 54 Pegylated Interferon 54 alfuzosin 54 Phase 2a trial 54 Synavive 54 nabilone 54 Durezol 54 Randomized trials 54 metastatic hormone refractory 54 cardioprotective effects 54 Phenoptin 54 conjugated estrogen 54 Alkeran 54 R#/MEM # 54 events SAEs 54 ARCOXIA 54 fluvastatin 54 Ticagrelor 54 levocetirizine 54 Bicifadine 54 antiangiogenic therapy 54 insulin lispro 54 Safinamide 54 Isolagen Therapy 54 Tolerability 54 glargine 54 MEND CABG 54 lipid lowering agents 54 tamsulosin 54 Phase 1b clinical trials 54 degarelix 54 landmark ATHENA 54 phase 2a 54 evaluating REVLIMID 54 low dose cytarabine 54 ABSORB trial 54 methotrexate monotherapy 54 enzastaurin 54 metastatic castration resistant 54 IV bisphosphonates 54 adipiplon 54 initiate Phase 2b 54 Protelos 54 randomized controlled clinical trials 54 adalimumab Humira 54 inhibitor RG# 54 ispinesib administered 54 fluoropyrimidine 54 Panzem NCD 54 diarrhea vomiting nausea 54 NeuroSTAT ® 54 RIO Lipids 54 mg doses 54 lucinactant 54 Launches Generic Version 54 Cloretazine ® 54 candidate TNFerade biologic 54 Taxol paclitaxel 54 antiretroviral naïve 54 CALGB # [002] 54 ibandronate 54 XGEVA 54 Tyrima 54 KNS # 54 BENICAR HCT 54 transdermal estradiol 54 pregabalin 54 placebo p = 54 inhaled AAT 54 Toxicities 54 discontinuations due 54 headache somnolence 54 cilostazol 54 telaprevir dosing 54 Desvenlafaxine Succinate 54 rapid virologic response 54 HBeAg seroconversion 54 micafungin 54 JAK#/JAK# inhibitor CYT# 54 senicapoc 54 statistically significant improvement 54 perampanel 54 Tekamlo 54 headache tiredness dizziness 54 Traficet EN 54 mg/# mg [001] 54 lopinavir r arm 54 Dual antiplatelet therapy 54 mesalamine granules 54 ASCEND HF 54 Heterozygous Familial Hypercholesterolemia 54 cetuximab Erbitux 54 High Dose quadruples 54 SUSTENNA TM 54 ALVESCO 54 ruboxistaurin 54 Perforomist ™ Inhalation Solution 54 Flu Cy 54 ANCHOR trial 54 refractory colorectal cancer 54 Empatic 54 LCP AtorFen 54 Prodarsan ® 54 HCV SPRINT 54 mg eq 54 TransVax ™ 54 azacitidine 54 talabostat 54 lumiracoxib 54 PROMACTA 54 virologic response 54 intravascular hemolysis 54 Peginterferon alfa 2a 54 PF # [002] 54 ACR# responses 54 lintuzumab SGN 54 Patients Treated With 54 TELCYTA 54 PRIMO CABG 54 anidulafungin